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AbstrAct
Objectives To investigate whether an authorship effect 
is found that leads to better performance in studies 
conducted by the original developers of the Patient Health 
Questionnaire (PHQ-9) (allegiant studies).
Design Systematic review with random effects bivariate 
diagnostic meta-analysis. Search strategies included 
electronic databases, examination of reference lists and 
forward citation searches.
Inclusion criteria Included studies provided sufficient 
data to calculate the diagnostic accuracy of the PHQ-9 
against a gold standard diagnosis of major depression 
using the algorithm or the summed item scoring method at 
cut-off point 10.
Data extraction Descriptive information, methodological 
quality criteria and 2×2 contingency tables.
results Seven allegiant and 20 independent studies 
reported the diagnostic performance of the PHQ-9 using 
the algorithm scoring method. Pooled diagnostic OR 
(DOR) for the allegiant group was 64.40, and 15.05 for 
non-allegiant studies group. The allegiance status was a 
significant predictor of DOR variation (p<0.0001). Five 
allegiant studies and 26 non-allegiant studies reported 
the performance of the PHQ-9 at recommended cut-off 
point of 10. Pooled DOR for the allegiant group was 49.31, 
and 24.96 for the non-allegiant studies. The allegiance 
status was a significant predictor of DOR variation 
(p=0.015). Some potential alternative explanations for 
the observed authorship effect including differences in 
study characteristics and quality were found, although it 
is not clear how some of them account for the observed 
differences.
conclusions Allegiant studies reported better 
performance of the PHQ-9. Allegiance status was 
predictive of variation in the DOR. Based on the observed 
differences between independent and non-independent 
studies, we were unable to conclude or exclude that 
allegiance effects are present in studies examining the 
diagnostic performance of the PHQ-9. This study highlights 
the need for future meta-analyses of diagnostic validation 
studies of psychological measures to evaluate the impact 
of researcher allegiance in the primary studies.
Research on allegiance effects has a long 
tradition in psychotherapy research. In this 
context, allegiance describes the phenomenon 
that researchers and clinicians who devel-
oped a treatment approach or are for other 
reasons invested in it tend to find larger effect 
sizes in favour of their treatment than for 
comparison groups.1 This finding has been 
extensively replicated2 3 and is also robust 
when the quality of research is controlled for. 
Researcher allegiance is subject of ongoing 
debates about the design of efficacy studies as 
well as implications for policy.2 4 5 Researcher 
allegiance is also discussed widely in the liter-
ature on experimental as well as evaluation 
research.6 Since the motivational underpin-
nings of allegiance effects are potentially far 
more ingrained into human behaviour and 
decision making than previously thought,7 
they may occur commonly in clinical research 
in general.
Although it has been suggested that alle-
giance effects may play a role in the validation 
of psychological screening and case-finding 
tools (eg, O'Shea et al., in press), systematic 
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Research
strengths and limitations of this study
 ► An original study—the first meta-analysis of 
diagnostic validation studies of psychological 
measures to evaluate the impact of researcher 
allegiance.
 ► Using rigorous methodology—strict inclusion/
exclusion and quality assessment criteria.
 ► We found that the allegiance effect was a significant 
predictor of the variation of the diagnostic OR in the 
meta-regression analysis.
 ► Substantial variability observed in methodological 
quality of included studies.
 ► Based on the observed methodological differences 
between the independent and non-independent 
studies, we were unable to conclude or exclude that 
allegiance effects are present in studies examining 
the diagnostic performance of the Patient Health 
Questionnaire (PHQ-9).
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evaluations of this hypothesis are rare and studies that 
acknowledge potential allegiance effects in such studies 
mainly come from forensic psychology and psychiatry 
backgrounds.8–11 Diagnostic validation studies are geared 
at establishing the sensitivity and specificity of a screening 
or case-finding tool, which is used in practice to differ-
entiate cases from non-cases or to decide about whether 
further assessment or treatment is indicated or will be 
offered. An allegiance effect in such studies would be 
seen in systematically higher sensitivities or specificities 
if the original author(s) is (are) part of the team of such 
a study. Such a bias would have a deleterious affect on 
practice through promising overoptimistic accuracy of 
the screening or case-finding tool or in evaluating the 
cost-effectiveness of the measure in a screening or case-
finding context.
The depression module of the Patient Health Ques-
tionnaire (PHQ-9) is a widely used depression-screening 
instrument in non-psychiatric settings. The PHQ-9 was 
developed by a team of researchers, with its development 
underwritten by an educational grant from Pfizer US Phar-
maceuticals.12 The PHQ-9 can be scored using different 
methods, including an algorithm based on Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV criteria 
and a cut-off based on summed-item scores. The psycho-
metric properties of these two approaches have been 
summarised in two recently published meta-analyses.13 14 
The goal of the current review is to investigate, based on 
an established database of PHQ-9 diagnostic validation 
studies,13 14 whether an allegiance effect is found that 
leads to an increased sensitivity and specificity in studies 
that were conducted by researchers closely connected to 
the original developers of the instrument.
MethODs
study selection
Similar search strategies were used in both systematic 
reviews (for full details, please see Manea et al and Mori-
arty et al13 14). Embase, Medline and PsycINFO were 
searched from 1999 (when the PHQ-9 was first devel-
oped) to August 2013 and September 2013, respectively, 
using the terms ‘PHQ-9’, ‘PHQ’, ‘PHQ$’ and ‘patient 
health questionnaire’. The search strategy is presented 
in online supplementary appendix 1. The reference lists 
of studies fitting the inclusion criteria were manually 
searched and a reverse citation search in Web of Science 
was performed. The authors of unpublished studies were 
contacted and conference abstracts were reviewed in an 
attempt to minimise publication bias.
The following inclusion-exclusion criteria were used:
Population: adult population. Instrument: studies that 
used the PHQ-9. Comparison (reference standard): the accu-
racy of the PHQ-9 had to be assessed against a recognised 
gold-standard instrument for the diagnosis of either DSM 
or International Classification of Disease (ICD) criteria for 
major depression. Studies were included if the diagnoses 
were made using a standardised diagnostic structured 
interview schedule (eg, Mini International Neuropsychi-
atric Interview (MINI), Structured Clinical Interview for 
DSM Disorders (SCID)). Unguided clinician diagnoses 
with no reference to a standard structured diagnostic 
schedule or comparisons of the PHQ-9 with other self-re-
port measures were excluded. Studies were also excluded 
if the target diagnosis was not major depressive disorder 
(MDD, eg, any depressive disorder). Outcome: studies had 
to report sufficient information to calculate a 2×2 contin-
gency table for the algorithm or the recommended cut-off 
point 10. Study design: any design. Additional criterion: we 
avoided double counting of evidence by ensuring that 
only one study of those that reported overlapping data-
sets in different journals were included in the meta-anal-
ysis. Citations with overlapping samples were examined 
to establish whether they contained information relevant 
to the research question that was not contained in the 
included report.
Quality assessment
Quality assessment was performed using the Quality 
Assessment of Diagnostic Accuracy Studies (Revised) 
(QUADAS-2) tool, a tool for evaluating the risk of bias 
and applicability of primary diagnostic accuracy studies 
when conducting diagnostic systematic reviews.15 It covers 
the areas of patient selection, index test, reference stan-
dard and flow and timing.16 This tool was adapted for the 
two reviews and quality assessments were carried out by 
two independent reviewers for all studies included in the 
reviews.
Data synthesis and statistical analysis
We constructed 2×2 tables for cut-off point 1014 and the 
algorithm scoring method.13 Pooled estimates of sensi-
tivity, specificity, positive/negative likelihood ratios and 
diagnostic ORs (DOR) were calculated using random 
effects bivariate meta-analysis.17 Heterogeneity was 
assessed using I2 for the DOR, an estimate of the propor-
tion of study variability that is due to between-study vari-
ability rather than sampling error. We considered values 
of ≥50% to indicate substantial heterogeneity.18 Summary 
receiver operating characteristic curves (sROC) were 
constructed using the bivariate model to produce a 95% 
confidence ellipse within ROC space.19 Each data point 
in the sROC space represents a separate study, unlike a 
traditional ROC plot, which explores the effect varying 
thresholds on sensitivity and specificity in a single study.
We undertook a meta-regression analysis of logit DOR 
using research allegiance as covariate in the meta-regres-
sion model.20 21 Analyses were conducted using STATA 
V.12, with the metan, metandi and metareg user-written 
commands.
Allegiance rating
We rated authorship on a paper if any of the developers 
of the PHQ-9—Kurt Kroenke, MD, Robert L Spitzer, 
MD and Janet BW Williams—as an indicator of poten-
tial allegiance. We also rated as evidence of allegiance as 
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acknowledged collaborations with the developers of the 
PHQ-9, even if they were not listed as coauthors or if the 
authors acknowledged funding from Pfizer to conduct 
the study.
results
Overview of included studies
Thirty-one studies reported the diagnostic properties of 
the PHQ-9 at cut-off point 10 or above and were included 
in this analysis.14 Twenty-seven studies were included in 
the algorithm review.13 The study selection flow charts can 
be found in online supplementary appendix 2 (figures 1 
and 2). The characteristics of these studies are reported 
in tables 1 and 2 and the results of the methodological 
assessment are presented in tables 3 and 4.
Algorithm scoring method
Descriptive characteristics
The descriptive characteristics of the included studies 
are presented in table 1. Seven individual studies that 
reported the diagnostic performance of the PHQ-9 
using the algorithm scoring method were coauthored 
by the original developers of the PHQ-9,22–26 specifically 
acknowledged one of the developers and support by an 
educational grant from Pfizer USA,27 or were coauthored 
by the first author of a previous study that had also been 
coauthored by one of the developers.28 Twenty non-alle-
giant studies reported the diagnostic properties of the 
PHQ-9 using the algorithm scoring method.
Three (43%, 3/7) of the allegiant studies were 
conducted exclusively in hospital settings.22 26 28 The 
remaining four studies (67%, 4/7) were conducted in 
different settings or non-exclusively hospital settings: one 
in primary care25 and three in mixed settings: psycho-
somatic walk in clinics and family practices23,i outpa-
tient clinics and family practices24 and primary care and 
hospital settings.27 In the non-allegiant group, 13 (65%, 
13/20) studies were conducted in hospital settings.29–41 
Of the remaining seven studies, six were conducted 
in primary care settings42–47 and one in a community 
sample.48
In both groups (non-allegiant and allegiant studies), 
the majority of studies validated a translated version 
of the PHQ-9. Two of the studies authored by devel-
opers (28%, 2/7),25 26 and eight (40%, 8/20) allegiant 
studies29 30 37–40 42 48 were conducted in English.
The mean prevalence of MDD in the group of allegiant 
studies was 13.4% (range 6.1%–29.2%); in the non-alle-
giant group it was 15.5% (range 3.9%–32.4%). The mean 
age of patients in the PHQ-9 developers group was 45.7; all 
but one study had a mean age in the range of 40–50 years. 
In the non-allegiant group, the mean age was 54.6 (range 
i  This study provided separate estimates for the two settings in which it 
was conducted; therefore separate psychometric estimates were gener-
ated for each sample for both algorithm scoring method and summed 
items scoring method at cut-off point 10 (see below).
29.3–75.0), with almost half (8) of the studies reporting 
a mean age of over 60. The percentage of females in the 
PHQ-9 developers was 56.8% (range 28.6%–67.8%) and 
in the non-allegiant group was 59.1 (18%–100%).
All allegiant studies used a self-reported PHQ-9, whereas 
in seven non-allegiant studies (30%, 6/20) the PHQ-9 
was administered by a researcher.30–33 43 48 Apart from 
Muramatsu et al., all allegiant studies used the SCID as 
a gold standard27; the non-allegiant studies used a wider 
range of gold standards including SCAN, CIDI, MINI and 
C-DIS, although the SCID was also frequently used by the 
independent studies as well (45%, 9/20 studies).
Four out of the seven allegiant studies (57%) did not 
include a conflict of interest statement.22 23 25 27 Also, four 
(57%) of the allegiant studies acknowledged funding 
from Pfizer.23–25 27 Only one study27 acknowledged the 
collaboration with one of the developers of the PHQ-9.
Of the non-allegiant studies, 12 (60%) did not include 
a conflict of interest statement.29–32 35–37 39 44–46 48 It appears 
that newer studies were more likely to include a conflict 
of interest statement, which may reflect a recent change 
in reporting. Funding was acknowledged by most studies 
(18/20) and most received funding from academic or/
and health research institutions. Two studies received 
funding from pharmaceutical companies—Lundbeck43 
and Pfizer35 and one study acknowledged that Pfizer 
Italia provided the Italian version of PHQ-9 and gave the 
authors permission to use it.36
Diagnostic test accuracy
Pooled sensitivity and specificity was calculated separately 
for the non-allegiant and allegiant studies. Pooled sensi-
tivity for the allegiant studies of the PHQ-9 was 0.77 (95% 
CI 0.70 to 0.84), pooled specificity was 0.94 (95% CI 0.90 
to 0.97) and the pooled DOR was 64.40 (95% CI 34.15 
to 121.43). Heterogeneity was high (I²=78.9%). Figure 1 
represents the sROCs for this set of studies.
Pooled sensitivity for the non-allegiant studies was lower 
compared with the developer authored studies group at 
0.48 (95% CI 0.41 to 0.91), pooled specificity was the 
same at 0.94 (95% CI 0.91 to 0.95). The pooled DOR was 
approximately four times lower at 15.05 (95% CI 11.03 
to 20.52) (see figure 1). Heterogeneity was substantial at 
I²=68.1%.
The meta-regression analysis for algorithm studies with 
non-allegiant status as the predictor of the DOR showed 
that non-allegiant status was a significant predictor of the 
DOR (p<0.0001) and explained a substantial amount of 
the observed heterogeneity (51.5%).
Quality assessment
The results of the quality assessment using QUADAS-2 
are given in table 3 for the studies reporting on the diag-
nostic performance of the algorithm scoring method. In 
the patient selection domain, more non-allegiant studies 
(65%, 13/20) than allegiant (29%, 2/7) met the criterion 
for consecutive referrals. There were no marked differ-
ences on the other two criteria in this domain (avoid 
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Figure 1 Patient Health Questionnaire-9 algorithm scoring method summary receiver operating characteristic plot for the 
diagnosis of major depressive disorder in allegiant studies (panel A) and non-allegiant studies (panel B). Pooled sensitivity and 
specificity estimates using a bivariate meta-analysis. HSROC, hierarchical receiver operating characteristic.
case-control design, avoid inappropriate exclusions). In 
the index test domain, the proportion of studies reporting 
that the PHQ-9 was conducted blind to the reference 
test was comparable between the two groups. There 
were differences in this domain for those studies using 
a translated version of the test. All non-English allegiant 
studies (5/5) used an appropriately translated version of 
the PHQ-9, whereas just over a half of the non-allegiant 
studies reported this (55%, 6/11). However, the majority 
of both sets of studies did not report details of psycho-
metric properties of the translated version. For the refer-
ence test domain, nearly all studies in both groups were 
rated as using a reference test that would correctly clas-
sify the condition. While most allegiant studies reported 
that the reference test was interpreted blind to the PHQ-9 
score (86%, 6/7), this was reported in only 60% (12/20) 
of the non-allegiant studies.
The two sets of studies that used translated versions 
of the reference test were broadly comparable. There 
was a slight indication that the allegiant studies were 
more likely to use an appropriately translated version 
of the reference test and report data on the psycho-
metric properties of the translated version, although 
the numbers for the translated comparison are very 
low. There were, however, some more notable differ-
ences on the flow and timing domain. Most allegiant 
studies ensured that the time between the index and 
reference test was under 2 weeks (86%, 6/7) in compar-
ison to 70% (14/20) of the non-allegiant studies. More 
allegiant studies met the criterion for ‘all participants 
included in the analysis’ (57%, 4/7) than non-allegiant 
studies (25%).
summed items scoring method (cut-off point 10 or above)
Descriptive characteristics
Table 2 presents the sample characteristics of the 31 
PHQ-9 validation studies that reported the psychometric 
properties of the PHQ-9 at cut-off point 10 or above. 
Five of these studies were coauthored by the original 
developers of the instrument or acknowledged collabo-
ration12 23 26 49 or were coauthored by the first author of 
a previous study that had also been coauthored by one 
of the developers.28 Twenty-six studies were conducted by 
independent researchers.
Three (60%, 3/5) allegiant studies26 28 49 and 11 
non-allegiant studies (42%, 11/26)30–32 34 37 38 50–54 were 
conducted in hospital settings.
Three (60%, 3/5) allegiant studies12 26 49 and 13 non-al-
legiant studies (13/26)30 37 38 42 48 51–53 55–59 were conducted 
in English.
The mean prevalence of MDD in the allegiant group 
was 13.2% (range 6.1%–33.5%) and in the non-alle-
giant group was 16.1% (range 2.5%–43.2%). The mean 
age of patients in the allegiant group studies was 48.1 
(range 41.9–61.0) and in the 26 non-allegiant studies 
that reported these data was 49.1 (range 23.0–78.0). 
The percentage of females in the allegiant studies that 
reported these data12 23 26 28 was 56.3% (range 28.6%–
67.8%) and in the non-allegiant group was 64.9% (range 
12%–100%).
Three allegiant studies used the self-reported mode 
of administration and two of them did not specify how 
the PHQ-9 was administered. In nine non-allegiant 
studies (34%, 9/26), the PHQ-9 was administered by the 
researcher.30–32 48 56 58–61 All allegiant studies used SCID as 
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a gold standard; the non-allegiant studies used a wider 
range of gold standards including SCAN, CIDI, MINI, 
CIS-R, C-DIS, although the SCID was used in half of the 
studies (50%, 13/26 studies).
Three allegiant studies (60%) did not include a conflict 
of interest statement.12 23 49 Two of these studies12 23 
acknowledged funding from Pfizer. None of the allegiant 
studies acknowledged collaboration or authorship of one 
of the developers of the PHQ-9.
Of the non-allegiant studies, 13 (42%) did not include 
a conflict of interest statement.30–32 37 42 46 48 53 55 60 62–64 
Similar to the algorithm studies, the newer studies were 
more likely to include a conflict of interest statement. 
Funding was acknowledged by most studies (27/31) and 
most received funding from academic and/or health 
research institutions. One study57 acknowledged that the 
last author involved in the development of one of the 
instruments (CORE-OM), ‘but does not gain financially 
from its use’. One study51 acknowledged funding from 
industry, AHA Pharmaceuticals Roundtable, but stated 
that ‘the funding organisations had no role in the design 
or conduct of the study, collection, management, anal-
ysis or interpretation of data; or preparation, review or 
approval of the manuscript. Fine et al. disclosed that the 
last author had financial and consulting interests (Pfizer 
was not cited as one of them).56
Diagnostic test accuracy
Pooled sensitivity of allegiant studies was 0.87 (95% CI 
0.77 to 0.93), pooled specificity was 0.87 (95% CI 0.76 
to 0.94) and the pooled DOR was 49.31 (95% CI 25.74 
to 94.48)—see table 5. Heterogeneity was moderate 
(I²=55.1%). Figure 2 represents the sROCs for this group.
Pooled sensitivity of non-allegiant studies was 0.76 (95% 
CI 0.67 to 0.83), pooled specificity was 0.88 (95% CI 0.85 
to 0.91) and the pooled DOR was 24.96 (95% CI 14.81 
to 42.08), approximately half that of the allegiant studies 
(table 2). Heterogeneity was high at I²=81.5%. Figure 2 
represents the sROCs for this group.
The meta-regression for the studies using a cut-off point 
of 10 or above with allegiance status of the predictor 
showed that allegiance status was a significant predictor 
of the DOR (p=0.015) and explained 19.0% of observed 
heterogeneity.
Quality assessment
The results of the quality assessment using the QUADAS-2 
are given in table 4. For the patient selection domain, the 
two groups of studies were broadly comparable on two 
items (consecutive or random sample, avoid case-con-
trol design). However, all allegiant studies were rated as 
avoiding inappropriate exclusions (5/5) in contrast to 
58% (15/26) of the non-allegiant studies.
On the index test domain, there were a number of 
differences between the two groups of studies. More of 
the non-allegiant studies (81%, 21/26) reported that 
the PHQ-9 was interpreted blind to the reference test 
compared with 60% (3/5) of the allegiant studies. All 
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Figure 2 Patient Health Questionnaire-9 summed items scoring method at cut-off point 10 summary receiver operating 
characteristic plot for diagnosis of major depressive disorder in allegiant studies (panel A) and non-allegiant studies (panel B). 
Pooled sensitivity and specificity using a bivariate meta-analysis. HSROC, hierarchical receiver operating characteristic.
(5/5) allegiant studies were rated as prespecifying the 
threshold on the PHQ-9 compared with 73% (19/26) 
of the non-allegiant studies. The two sets of studies were 
broadly comparable in terms of two items from the refer-
ence test domain (correctly classify target condition, refer-
ence test interpreted blind). Only one allegiant study used 
a translated version of the index test or reference test, 
so it is not possible to comment on differences between 
the two sets of studies in terms of these items from the 
index or reference test domains. For the flow and timing 
domain, the two groups of studies were broadly compa-
rable for two of the criteria (interval of 2 weeks or less, all 
participants receive same reference test). However, fewer 
than half of the non-allegiant studies met the criterion for 
‘all participants included in the analysis’ (42%, 11/26), 
whereas all allegiant studies met this criterion.
DIscussIOn
This is to our knowledge the first systematic examination 
of a possible ‘allegiance’ or authorship effect in the vali-
dation of screening or case-finding psychological instru-
ment for a common mental health disorder. We reviewed 
diagnostic validation studies of the PHQ-9, a widely used 
depression screening instrument. We found that allegiant 
studies reported higher sensitivity paired with similar 
specificity compared with non-allegiant studies. When 
entered as a covariate in meta-regression analyses, alle-
giance status was predictive of variation in the DOR for 
both the algorithm scoring method and the summed-
item scoring method at a cut-off point of 10 or above.
Previous research has proposed several possible expla-
nations for the allegiance effect.9–11 One possibility is the 
advertent bias that may serve to inflate the performance 
of a test when evaluated by those who have developed it. 
However, before concluding that the differences are due 
to this, it is important to explore and rule out alternative 
explanations. First, it is possible that any observed differ-
ences are a result of differences in study characteristics of 
the two sets of studies (eg, setting, clinical population). 
Second, differences in the methodological quality of the 
studies may also account for any differences. These possi-
bilities are examined below.
Difference in study characteristics as potential alternative 
explanations
The two sets of studies were broadly comparable in terms 
of gender and the prevalence of depression, so these vari-
ables are unlikely to offer an explanation for the differ-
ences. While there were some indications from both sets 
of comparisons that the PHQ-9 may have been research-
er-administered more often in the independent studies, 
it is not immediately clear how this would lead to lowered 
diagnostic performance.
The diagnostic meta-analyses of the PHQ-913 14 have 
shown that the sensitivity and DOR of the PHQ-9 tends 
to be lower in hospital settings for both algorithm and 
summed-item scoring methods. While the fact that 
proportionally more non-allegiant algorithm studies were 
conducted in secondary care could explain the lower 
sensitivity and DOR values in the algorithm studies, in 
the studies that reported the cut-off point of or above this 
would not be the case as proportionally more allegiant 
studies were conducted in hospital settings.
Similarly, differences in the proportions of studies using 
translated versions of the PHQ-9 are also unlikely to offer 
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an obvious explanation of the difference in diagnostic 
performance, because in the algorithm set of studies 
more of the allegiant studies used a translated version of 
the test, but the proportions were in the opposite direc-
tion for the studies using a cut-off of 10 or above. We 
tested this by carrying out a sensitivity analysis restricting 
the sample to English studies and studies with adequate 
translation. The allegiance effect was still predictive of 
DOR variation between allegiance and non-allegiance 
studies variation in both algorithm (p=0.00) and summed 
item scoring at cut-off point of 10 meta-analyses (p=0.02).
A similar conclusion is also likely to apply to the age 
of the samples. There were more older adults studies in 
the non-allegiant than allegiant studies in the algorithm 
comparison. Depression could be more difficult to iden-
tify in older adults due to physical comorbidities that 
may present with similar symptomatology to depression 
and could account for the lower diagnostic performance 
in the non-allegiant studies. However, the non-allegiant 
samples in the studies that reported the psychometric 
properties at cut-off point 10 or above had younger 
samples than the allegiant studies, so this would not 
support this interpretation.
The SCID was used as the gold standard in nearly all 
allegiant studies. The fact that some non-allegiant studies 
used other gold standards could potentially explain the 
poorer psychometric properties of the PHQ-9 in these 
studies. The SCID is often regarded as the most valid of 
the available semi-structured interviews used in depres-
sion diagnostic validity studies as the reference standard. 
If we assume that this is the case and, furthermore, that 
the PHQ-9 is an accurate method of screening for depres-
sion, then the PHQ-9 may be more likely to agree with the 
SCID than other reference standards. However, when we 
carried out a sensitivity analysis restricting the sample to 
SCID-only studies, the allegiance effect was still predictive 
of DOR variation between allegiance and non-allegiance 
studies variation in both algorithm (p=0.01) and summed 
item scoring at cut-off point of 10 reviews (p=0.02).
Differences in methodological quality as potential alternative 
explanations
The quality of the studies was evaluated using the 
QUADAS-2. Although there were several potential meth-
odological differences between the two groups of studies 
from the algorithm papers, not all of these offer obvious 
explanations of the observed differences and some are 
unlikely as explanations. For example, more allegiant 
studies ensured that the reference test was interpreted 
blind to the index test. This is unlikely to account for 
the observed differences, because a lack of blinding is 
typically associated with artificially increased diagnostic 
performance, which is in the opposite direction to the 
pattern of results observed here. The impact of some 
other differences is less clear-cut. For example, a higher 
number of the non-allegiant studies met the criterion for 
consecutive referrals. For this to provide an explanation 
of the observed differences, the non-consecutive nature 
of the referrals in the studies by those who had developed 
the PHQ-9 would need to have led to the overinclusion of 
true positives or underinclusion of false negatives given 
that these studies tended to report higher sensitivity 
relative to the non-allegiant studies (and vice versa for 
the independent studies). It is not immediately obvious 
how this would occur. The allegiant studies were more 
likely to have met the criterion of ‘included all partici-
pants in the analysis’. It is possible that the greater loss 
of participants from the non-allegiant studies may have 
artificially reduced the observed diagnostic accuracy, 
although, again, it is not immediately obvious how this 
would have affected the true positive and false negative 
rates. Although there is not an obvious explanation of 
how these differences in methodological quality could 
account for the observed differences in diagnostic perfor-
mance, it is important to recognise that they cannot on 
that basis be ruled out.
There are, however, two differences in methodolog-
ical quality among the algorithm studies that are clearer 
potential alternative explanations. The higher rate of 
appropriate translations among the allegiant studies is 
potentially important, because lower diagnostic estimates 
may be expected from studies that have poorly translated 
versions of the index test. In the flow and timing domain, 
more allegiant studies ensured that there was a less than 
2-week interval between the index and reference test. 
This is consistent with lower diagnostic performance in 
the non-allegiant studies: as the interval increases it is 
likely that depression status may change and this would 
lead to lower levels of agreement between the index test 
and the reference test.
There were also differences on some quality assessment 
items between the two sets of studies in the summed item 
scoring method comparison. The threshold was reported 
as prespecified in all allegiant studies in contrast to 
approximately three-quarters of the non-allegiant studies. 
On the face of it, this is unlikely to explain the observed 
differences, because the use of a prespecified cut-off point 
is likely to be associated with lower not higher diagnostic 
test performance. One possibility, however, is that studies 
that performed poorly at this cut-off point were less likely 
to be reported by those who had developed the measure. 
As discussed in more detail in the 'Limitations' section, we 
were unable to explore this possibility through the use of 
formal tests for publication bias.
All allegiant studies avoided inappropriate exclusions 
compared with approximately half of the non-allegiant 
studies. While this is a potential alternative explanation 
of the differences, it is not immediately obvious how this 
would explain the differences in diagnostic performance 
between the two sets of studies. Fewer than half of the 
non-allegiant studies met the criterion for ‘all partici-
pants included in the analysis’, in contrast to all of the 
allegiant studies met this criterion, but again this differ-
ence should usually work against the inclusive studies, not 
those excluding cases. More of the non-allegiant studies 
reported that the PHQ-9 was interpreted blind to the 
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reference test. This does offer a potential explanation, 
because the absence of blinding may artificially inflate 
diagnostic accuracy.
lIMItAtIOns
The results of this review need to be viewed in light of 
the limitations of the primary studies that contributed 
to the review and the review itself. An important consid-
eration is to establish whether any observed differences 
between the diagnostic performance of the non-al-
legiant and allegiant studies are better accounted for 
by study characteristic or methodological differences. 
Caution, however, is needed in interpreting any differ-
ences, because of the small number of allegiant studies 
in both the algorithm and cut-off 10 or above compari-
sons. The small number of allegiant studies also meant 
that we were also unable to explore the potential role 
of publication bias in the non-allegiant and allegiant 
studies. At least 10 studies are required to use standard 
methods of examining publication bias, but the number 
of allegiant studies in both the algorithm and cut-off 
10 or above comparisons were fewer than this. Papers 
published from August 2013 onwards are not covered 
in the literature search used and so it potentially misses 
some more recent studies that would be eligible for 
inclusion, although it is unlikely that many, if any, new 
allegiant studies have been published since.
cOnclusIOns AnD IMplIcAtIOns fOr further reseArch
The aims of the review was to investigate whether an 
allegiance effect is found that leads to an increased 
diagnostic performance in diagnostic validation studies 
that were conducted by teams connected to the orig-
inal developers of the PHQ-9. Our analyses showed 
that diagnostic studies conducted by independent/
non-allegiant researchers had lower sensitivity paired 
with similar specificity compared with studies that were 
classified as allegiant. This conclusion held for both the 
algorithm and cut-off 10 or above studies. We explored 
a range of possible alternative explanations for the 
observed allegiance effect including both differences 
in study characteristics and study quality. A number of 
potential differences were found, although for some of 
these it is not clear how they would necessarily account 
for the observed differences. However, there were a 
number of differences that offered potential alternative 
explanations unconnected to allegiance effects. In the 
algorithm studies, the studies rated as allegiant were 
also more likely to use an appropriate translation of 
the PHQ-9 and were also more likely to ensure that the 
index and reference test were conducted within 2 weeks 
of each other, both of which may be associated with an 
improvement in observed diagnostic performance of an 
instrument. The majority of studies in both meta-anal-
yses did not provide clear statements about potential 
conflict of interest and/or funding; however, the newer 
studies were more likely to provide such statements, 
which may reflect increasing transparency in this area 
of research.
We cannot, therefore, conclude that allegiance effects 
are present in studies examining the diagnostic perfor-
mance of the PHQ-9; but nor can we rule them out. 
Conflicts of interest are an important area of investiga-
tion in medical and behavioural research, particularly 
due to concerns about trial results being influenced by 
industry sponsorship. Future diagnostic validity in this 
area should as a matter of routine present clear state-
ments about potential conflicts of interest and funding, 
particularly relating to the development of the instru-
ment under evaluation. Future meta-analyses of diag-
nostic validation studies of psychological measures 
should routinely evaluate the impact of researcher 
allegiance in the primary studies examined in the 
meta-analysis.
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